NeoSpect
depreotide
Table of contents
Overview
The marketing authorisation for NeoSpect has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
NeoSpect
|
| Agency product number |
EMEA/H/C/000263
|
| Active substance |
depreotide trifluoroacetate
|
| International non-proprietary name (INN) or common name |
depreotide
|
| Therapeutic area (MeSH) |
Radionuclide Imaging
|
| Anatomical therapeutic chemical (ATC) code |
V09IA05
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
CIS bio international
|
| Revision |
10
|
| Date of issue of marketing authorisation valid throughout the European Union |
29/11/2000
|
| Contact address |
Route Nationale 306, Saclay |
Product information
28/10/2010 NeoSpect - EMEA/H/C/000263 - N/0015
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Diagnostic radiopharmaceuticals
Therapeutic indication
This medicinal product is for diagnostic use only.
For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, in
combination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.